Related Experiment Videos
Antihypertensive therapy and diabetic microvascular disease
1Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Vic, Australia.
Summary
Angiotensin-converting enzyme (ACE) inhibitors effectively prevent diabetic kidney disease progression, even with normal blood pressure. These agents offer protection against vascular injury in diabetes, making them a preferred treatment.
Area of Science:
- Nephrology
- Cardiology
- Endocrinology
Background:
- Hypertension frequently co-occurs with diabetes, contributing to diabetic vascular complications.
- Diabetic microvascular injury is a significant concern, exacerbated by hypertension.
Purpose of the Study:
- To investigate the role of hypertension in accelerating diabetic microvascular injury.
- To assess the efficacy of antihypertensive agents in preventing diabetic vascular abnormalities.
Main Methods:
- Studies involved experimental models (streptozotocin-induced diabetes in SHR) and clinical trials.
- Evaluated functional and structural parameters of nephropathy.
- Compared ACE inhibitors and dihydropyridine calcium channel blockers.
Main Results:
- ACE inhibitors, unlike dihydropyridine calcium channel blockers, favorably impacted experimental diabetic nephropathy progression, even with normal blood pressure.
- ACE inhibition attenuated trophic changes in mesenteric arteries of diabetic rats.
- Clinical data suggests ACE inhibitors are more effective than calcium channel blockers in reducing albuminuria in diabetic patients.
Conclusions:
- ACE inhibitors are the preferred agents for preventing and treating diabetic renal disease.
- ACE inhibitors may provide protection against vascular injury at multiple sites in diabetic patients.